《港樓》黃竹坑海盈山單日沽出15夥 成交金額逾1.98億
由嘉里建設(00683.HK)、信置(00083.HK)、太古地產(01972.HK)及港鐵(00066.HK)合作發展的黃竹坑站海盈山,於上週六(5月31日)加推第6號價單,並於昨日(4日)正式發售。截至昨日約下午6時,已沽出14夥。連同成交標售的單位,項目單日成交金額逾1.98億元。
昨日以價單形式售出之單位均爲實用面積582平方尺的兩房梗廚戶型。此外,項目同日以招標形式成功售出1夥高層三房一套連工作間之單位。該單位實用面積爲915平方尺,成交價爲3,180萬元,實用面積尺價約34,754元。
海盈山現時已屆現樓,並已啓動交樓程序。項目至今累計售出246夥,總成交金額逾36億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.